Associated tags: Engineering, Biotechnology, Stevanato Group, Health, Pharmaceutical, NYSE, Pharmaceutical industry, Medical Supplies, Manufacturing, Webcast, Science, Packaging, Conference, PIN
Locations: PENNSYLVANIA, SAN FRANCISCO, CALIFORNIA, MASSACHUSETTS, USA, ITALY, EUROPE, UNITED STATES
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the Bank of America Securities Healthcare Conference taking place from Tuesday, May 14, 2024 to Thursday, May 16, 2024.
- The Company will present on Wednesday, May 15, 2024 at 11:20 a.m. (PT).
- A live webcast will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section.
- A replay of the webcast will be available for approximately 90 days after the event.
Health,
Other Science,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
Conference call,
Webcast,
HD,
Conference,
PIN Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET).
- Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9, 2024, to discuss financial results.
- During the call, management will refer to a slide presentation which will be available on the morning of the call on the “Financial Results” page under the Company's Investor Relations section of its website.
- Webcast: A live, listen-only webcast of the call will be available at the following link: STVN webcast .
Medical Supplies,
Medical Devices,
Health,
Other Health,
Pharmaceutical,
Biotechnology,
Organization,
DiaSorin,
Growth,
Stevanato Group,
Information,
Piombino Dese,
Ugo,
Investment,
Multimedia,
Development,
Management Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO).
- View the full release here: https://www.businesswire.com/news/home/20240404727049/en/
Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire)
The addition of Ugo Gay underscores Stevanato Group’s unwavering commitment to driving operational efficiency, process standardization, and sustainable growth across its global value chain.
- Ugo Gay brings to Stevanato Group nearly three decades of experience in industry, business management, supply chain, and operations.
- “I am honored to help lead Stevanato Group's journey towards operational excellence, driving sustainable growth across our global footprint while fostering innovation," said Ugo Gay, Chief Operations Officer at Stevanato Group.
Medical Supplies,
Health,
Medical Devices,
Other Health,
General Health,
Pharmaceutical,
Biotechnology,
Citigroup,
BofA Securities,
Exercise,
Offering,
Form,
Telephone,
Stevanato Group,
William Blair & Company,
Sale,
Attention,
Security (finance),
Prospectus,
Morgan Stanley,
KeyBank,
Varick Street,
2nd Floor Stevanato Group sold 7,302,500 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), sold 7,302,500 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
Key Points:
- Stevanato Group sold 7,302,500 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), sold 7,302,500 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
- The total gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $379.7 million, or approximately $189.8 million from each of the Company Offering and the Selling Shareholder Offering.
- Stevanato Group will not receive any proceeds from the Selling Shareholder Offering.
- Morgan Stanley and William Blair served as lead book-running managers and as representatives of the underwriters for the Offering.
Medical Supplies,
Health,
Medical Devices,
Other Health,
General Health,
Pharmaceutical,
Biotechnology,
Citigroup,
BofA Securities,
Exercise,
Offering,
Form,
Telephone,
Stevanato Group,
William Blair & Company,
Sale,
Attention,
Security (finance),
Prospectus,
Morgan Stanley,
KeyBank,
Varick Street,
2nd Floor Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the pricing of its upsized underwritten public offering of an aggregate of 12,700,000 of its ordinary shares at a public offering price of $26.00 per share.
- Stevanato Group is offering 6,350,000 ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), which currently holds approximately 78% of Stevanato Group’s outstanding ordinary shares, is offering 6,350,000 ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
- Stevanato Group and the Selling Shareholder have granted the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase up to 1,905,000 additional ordinary shares on the same terms and conditions.
- Stevanato Group will not receive any proceeds from the Selling Shareholder Offering.
Retrieved on:
Wednesday, March 20, 2024
Medical Supplies,
Health,
Medical Devices,
Research,
Science,
Pharmaceutical,
Biotechnology,
Form,
Telephone,
Stevanato Group,
William Blair & Company,
Sale,
Attention,
Security (finance),
Prospectus,
Morgan Stanley,
Varick Street,
2nd Floor Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN) (“Stevanato Group,” or the “Company”), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the launch of an underwritten public offering of an aggregate of $300,000,000 of its ordinary shares.
- Stevanato Group is offering $150,000,000 of its ordinary shares (the “Company Offering”), and Stevanato Holding S.r.l., an affiliate and major shareholder of the Company (the “Selling Shareholder”), which currently holds approximately 78% of Stevanato Group’s outstanding ordinary shares, is offering $150,000,000 of its ordinary shares (the “Selling Shareholder Offering” and, together with the Company Offering, the “Offering”).
- Stevanato Group and the Selling Shareholder also intend to grant the underwriters an option, exercisable for 30 days after the date of the final prospectus supplement, to purchase additional ordinary shares up to an amount equal to 15% of the aggregate number of ordinary shares offered in the Offering on the same terms and conditions.
- Stevanato Group intends to use the net proceeds from the Company Offering for general corporate purposes, including to enable Stevanato Group to satisfy the requirements of its ongoing investment activities and working capital needs, and to ensure an appropriate level of operating and strategic flexibility.
Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum taking place from Tuesday, March 19, 2024 to Wednesday, March 20, 2024.
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum taking place from Tuesday, March 19, 2024 to Wednesday, March 20, 2024.
- The Company will present on Tuesday, March 19, 2024 at 1:30 p.m. (ET).
- A live webcast will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section.
- A replay of the webcast will be available for approximately 90 days after the event.
Biotechnology,
Pharmaceutical,
Health,
Conference call,
Biopharmaceutical,
COVID-19,
BDS,
PIN,
Investment,
Growth,
Syringe,
Segment,
Conference,
Glass,
Webcast,
Stevanato Group,
Public expenditure,
EPS,
Depreciation,
DCS Revenue for the fourth quarter of 2023 increased 10% to €320.6 million, and high-value solutions represented 37% of total revenue.
Key Points:
- Revenue for the fourth quarter of 2023 increased 10% to €320.6 million, and high-value solutions represented 37% of total revenue.
- For fiscal year 2023, revenue increased 10% to €1,085.4 million, and high-value solutions represented 34% of total revenue.
- Excluding revenue contributions from Covid-19, revenue grew approximately 24% in the fourth quarter of 2023, compared with the same period in 2022.
- Revenue from high-value solutions increased to 34% of total revenue for fiscal year 2023, compared with 30% last year.
Retrieved on:
Thursday, February 22, 2024
Biotechnology,
Pharmaceutical,
Medical Supplies,
Health,
Medical Devices,
Chemicals,
Plastics,
Health Technology,
Manufacturing,
HD,
Conference call,
PIN,
Conference,
Webcast Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET).
Key Points:
- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET).
- Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 7, 2024, to discuss financial results.
- We encourage participants to pre-register for the conference call using the following link: STVN conference call pre-registration .
- Webcast: A live, listen-only webcast of the call will be available at the following link: STVN webcast .
Retrieved on:
Wednesday, January 24, 2024
Technology,
Medical Devices,
General Health,
Professional Services,
Infectious Diseases,
Medical Supplies,
Clinical Trials,
FDA,
Diabetes,
Biotechnology,
Health,
Health Technology,
Hardware,
Radiology,
Pharmaceutical,
Finance,
Oncology,
Senior,
Stevanato Group,
Patient,
TEC,
Syringe,
Glass,
Multimedia,
Kit,
Safety,
Drug development,
F46,
Growth,
Fine chemical The surge the industry has seen in biopharmaceuticals treating various diseases in several therapeutical areas may signal a significant growth potential for pharmaceutical companies.
Key Points:
- The surge the industry has seen in biopharmaceuticals treating various diseases in several therapeutical areas may signal a significant growth potential for pharmaceutical companies.
- The kit will be available as a modular box made up of glass ready-to-use drug containers and add-on components on request, shipped by courier.
- EZ-fill® Kit will be presented at Pharmapack and is expected to be available commercially beginning in the second quarter of 2024.
- Additionally, to better support customers, Stevanato Group has introduced a non-GMP laboratory filling and finishing service at its Technology Excellence Centers (TEC) in Boston, USA, and Piombino Dese, Italy.
